My take of the Dec. 7th CC.
Not much new but what was
My take of the Dec. 7th CC.
Not much new but what was already known was well presented.
But the one thing new is a wondrous thing. The results from the one macaque treated with AAV leronlimab is even greater than it appears. A functional cure for HIV would be amazing. What about other long term diseases Long Covid, ME/CFS, Alzheimer's, Parkinson's, ALS, diabetes, recurrent cancers and so many more. Only one shot to help long suffering patients would be a blessing.
With just one subject in the study only scientists and doctors focusing on HIV are paying attention. Once a multi-subject study is done and the clinical holds are lifted proving safety that news should become widespread on HIV.
The future: The downside is that very long term HIV trials would need to be conducted to prove out safety in a drug that completely alters the immune system. Meanwhile Cytodyn can conduct it's other trials, gain approval and build up a war chest on it's 2031 expiration patent. Part of that war chest can be used to license the AAV patent from OHSU and will have further protection via that patent farther into the future.
23
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Overview of Equity Inducement Awards Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a leading biopharmaceutical organization, has recently initiated equity inducement awards to welcome new talent to its dynamic team. This initiative demonstrates Madrigal's commitment to fostering a strong workforce geared towards tackling significant health challenges related to metabolic...
Continue Reading
Boston Metal Appoints Industry Leader Roy Harvey Boston Metal, a prominent technology company that is transforming the landscape of global metals production, has made a significant move by appointing Roy Harvey to its Board of Directors. This decision is pivotal as Boston Metal gears up for the commercial rollout of its groundbreaking Molten Oxide Electrolysis (MOE)...
Continue Reading
RBL LLC Partners with Carnrite Ventures for Biotech Growth RBL LLC, a leading biotech venture creation studio, is excited to announce a significant investment from Carnrite Ventures. This partnership aims to enhance the rapid development of their robust pipeline of innovative therapeutic companies. According to Paul Wotton, the managing partner at RBL, "Carnrite's...
Continue Reading
Introducing the OncoC4 and AcroImmune Merger OncoC4, Inc. has just announced a thrilling merger with AcroImmune, a strategic union that promises to significantly boost OncoC4's standing in the biopharmaceutical sector. This collaboration brings together two companies dedicated to pioneering advancements in cancer treatment, with a special focus on developing unique...
Continue Reading
Rezolve AI Excited About $30 Billion AI Investment Rezolve AI (NASDAQ: RZLV), well-known for its cutting-edge AI-driven commerce solutions, is enthusiastic about the recent announcement from Microsoft and BlackRock. These influential tech companies plan to invest $30 billion into AI infrastructure, a decision that could profoundly alter the landscape of the artificial...
Continue Reading